Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 3/2010

01-09-2010 | Original Article

Glucose levels during oral glucose tolerance tests and gamma-glutamyl transpeptidase are predictors of change from normal to impaired glucose tolerance in healthy middle-aged Japanese men

Authors: Kentaro Watanabe, Kenzo Oba, Tatsuya Suzuki, Yuu Okuyama, Motoshi Ouchi, Kazunari Suzuki, Tetsuro Ohnishi, Masao Hashimoto, Yoshimasa Igari, Hiroshi Nakano

Published in: Acta Diabetologica | Issue 3/2010

Login to get access

Abstract

We evaluated the predictors of the development from normal to impaired glucose tolerance (IGT) in healthy middle-aged Japanese men. Forty male subjects who showed normal glucose tolerance (NGT) levels based on WHO criteria and who had undergone 75-g OGTT annually for 10 years were selected in the database of medical checkups retrospectively, and divided into two groups: those retaining NGT and those that developed IGT. Gamma-glutamyl transpeptidase (GGT) and the glucose levels at 30 and 60 min were significantly associated with the development of IGT in the Cox proportional hazard model. However, other clinical characteristics and the glucose levels at pre-load and at 120 min were not significantly associated with the development of IGT. GGT and the glucose levels at 30 and 60 min after the 75-g glucose load were predictors of development from NGT to IGT in healthy middle-aged Japanese men.
Literature
1.
Barr ELM, Zimmet PZ, Welborn TA et al (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116:151–157CrossRefPubMed
2.
Tominaga M, Igarashi K, Eguchi H, Kato T, Manaka H, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular diseases, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22:920–924CrossRefPubMed
3.
The DECODE study group on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621CrossRef
4.
World Health Organization: diabetes mellitus (1985) report of a WHO study Group. Tech Rep, Ser., no. 727, Geneva
5.
Igarashi Y, Mita T, Mizuno R et al (2005) Characteristics of Japanese subjects who progress from normal to impaired glucose tolerance. Longitudinal study excluding change in body weight. Endocr J 52:683–689CrossRefPubMed
6.
Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH (1999) A two-step model for development of non-insulin-dependent diabetes. Am J Med 90:229–235
7.
Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794CrossRefPubMed
8.
Ferrannini E, Gastaldelli A, Miyazaki Y et al (2003) Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 46:1211–1219CrossRefPubMed
9.
Kurose A, Fukushima M, Usami M (2003) Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 59:71–77CrossRefPubMed
10.
Matsumoto K, Yoshihiko Y, Miyake S et al (1997) Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 22:1562–1568CrossRef
11.
Suzuki H, Fukushima M, Usami M et al (2003) Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 26:1211–1215CrossRefPubMed
12.
Hirose T, Mizuno R, Yoshimoto T (2002) The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects. Endocr J 49:649–652CrossRefPubMed
13.
Lee D-H, Jacobs DR, Gross M et al (2003) γ-Glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 49:1358–1366CrossRefPubMed
14.
Nakanishi N, Suzuki K, Tatara K (2004) Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 27:1427–1432CrossRefPubMed
15.
Wannamethee SG, Shaper AG, Lennon L, Whincup PH (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28:2913–2918CrossRefPubMed
16.
Takahashi K, Uchiyama H, Yanagisawa S, Kaname S (2006) The logistic regression and ROC analysis of group-based screening for predicting diabetes incidence in four years. Kobe J Med Sci 52:171–180PubMed
17.
Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost H-G, Boeing H (2008) Liver enzymes and incident diabetes: findings from the European Prospective Investigation In to Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 31:1138–1143CrossRefPubMed
18.
Hanley A, Williams K, Festa A et al (2004) Elevations in markers of liver injury and risk of type 2 diabetes. Diabetes 53:2623–2632CrossRefPubMed
19.
Sattar N, Scherbakova O, Ford I et al (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 53:2855–2860CrossRefPubMed
20.
Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A (2000) Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 248:230–238CrossRefPubMed
21.
Orisawa M, Nakai N, Makoto T, Suwabe A (2006) Risk factors for development of pre-diabetic state from normal glucose regulation. Tohoku J Exp Med 210:279–283CrossRef
22.
Loguercio C, De Simone T, D’Auria MV et al (2004) Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 36:398–405PubMed
23.
Marchesini G, Forlani G (2002) NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35:497–499CrossRefPubMed
24.
Malnick SDH, Beergabel M, Knobler H (2003) Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. Q J M 96:699–709
25.
Su C, Wang K, Hsia T, Chen C, Tung T (2006) Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hypertension. J Clin Gastroenterol 40:551–554CrossRefPubMed
26.
André P, Balkau B, Born C, Charles E, Eschwège E (2006) Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 49:2599–2603CrossRefPubMed
27.
Weyer C, Tataranni PA, Bogardus C, Pratley RE (2001) Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24:89–94CrossRefPubMed
28.
Hotamisligil GS (2003) Inflammatory pathways and insulin action. Int J Obes 27:S53–S55CrossRef
29.
Ceriello A, Motz E (2004) Is oxidative stress the pathologic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24:816–823CrossRefPubMed
30.
Lee D-H, Blomhoff R, Jacobs DR (2004) Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 38:535–539CrossRefPubMed
Metadata
Title
Glucose levels during oral glucose tolerance tests and gamma-glutamyl transpeptidase are predictors of change from normal to impaired glucose tolerance in healthy middle-aged Japanese men
Authors
Kentaro Watanabe
Kenzo Oba
Tatsuya Suzuki
Yuu Okuyama
Motoshi Ouchi
Kazunari Suzuki
Tetsuro Ohnishi
Masao Hashimoto
Yoshimasa Igari
Hiroshi Nakano
Publication date
01-09-2010
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2010
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-009-0122-7

Other articles of this Issue 3/2010

Acta Diabetologica 3/2010 Go to the issue

Original Article

TAQIB and I405V polymorphisms of CETP are moderately associated with obesity risk in the Chinese adult population

Original Article

Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8)

Original Article

Clustering of cases of type 1 diabetes in high socioeconomic communes in Santiago de Chile: spatio-temporal and geographical analysis

Original Article

Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance

Original Article

Independent factors associated with depression in type 1 diabetes mellitus

Original Article

Serum levels of proamylin and amylin in normal subjects and patients with impaired glucose regulation and type 2 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits